BMED vs. ARKG

In the year-to-date period, BMED achieves a -4.34% return, which is significantly higher than ARKG's -4.86% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

BMED has a 0.85% expense ratio, which is higher than ARKG's 0.75% expense ratio.

This table presents a comparison of risk-adjusted performance metrics for Future Health ETF (BMED) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BMED Sharpe Ratio is -0.20, which is lower than the ARKG Sharpe Ratio of -0.14. The chart below compares the historical Sharpe Ratios of BMED and ARKG, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither BMED nor ARKG has paid dividends to shareholders.

The maximum BMED drawdown since its inception was -36.44%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for BMED and ARKG. For additional features, visit the drawdowns tool.

The current volatility for Future Health ETF (BMED) is 11.20%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 20.18%. This indicates that BMED experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.